Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield™ Multi-Cancer Detection (MCD) test in India. The collaboration aims to improve access to advanced cancer screening by enabling the early detection of multiple cancers through a simple blood test.
Zydus Lifesciences has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to make the Shield™ Multi-Cancer Detection (MCD) test available across India.
The test has been developed by Guardant Health, a global precision oncology company, and will be offered in India under an exclusive agreement with Zydus.
The partnership aims to improve access to advanced cancer screening and promote early diagnosis, which can lead to better treatment outcomes.
The Shield™ MCD test is a blood-based screening test that uses methylation technology to detect signals linked to multiple types of cancer.
The test is designed for people aged 45 years and above who are at an average risk of developing cancer.
It can screen for 10 common cancers, including:
The test requires only a single blood sample, making cancer screening more convenient and less invasive.
Read More: Varun Beverages Share Price in Focus; Announces Merger of Subsidiaries Bevco and Twizza!
Apollo Hospitals said early detection remains one of the most effective ways to improve cancer treatment outcomes. The hospital group believes expanding access to reliable screening can help identify cancer at an earlier and more treatable stage.
Zydus said the partnership reflects its commitment to strengthening cancer care in India by combining innovative diagnostics with greater public awareness about regular screening and preventive healthcare.
Guardant Health also noted that the test has the potential to support earlier clinical evaluation through a simple blood draw, helping transform cancer detection in the country.
Cancer continues to be one of India's leading health challenges.
According to the companies, more than 1.41 million people were diagnosed with cancer in India in 2022, while over 900,000 deaths were linked to the disease.
Breast cancer remains the leading cause of cancer-related deaths among women, while oral cancer is the most common cancer among men. Despite this, cancer screening rates remain low across many parts of the country, especially in northern, central and north-eastern regions.
The Shield™ MCD test has received the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for detecting eight cancer types. This designation recognises the technology's potential to improve cancer screening but does not represent FDA approval or clearance for commercial use.
Zydus Lifesciences is a global life sciences company focused on discovering, developing, manufacturing and marketing a wide range of healthcare products. The company employs more than 30,000 people worldwide, including around 1,500 research scientists, and continues to invest in innovation to improve patient care through advanced healthcare solutions.
On July 3, 2026, Zydus Lifesciences share price (NSE: ZYDUSLIFE) ended the session at ₹1,141.10, gaining ₹41.30 or 3.76% for the day. The stock opened at ₹1,105.00, touched an intraday high of ₹1,142.90, which is also its 52-week high, and slipped to a low of ₹1,104.10 during the session.
The partnership between Zydus Lifesciences and Apollo Hospitals marks an important step towards improving cancer screening in India. B
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 3, 2026, 3:31 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
